The Meb Faber Show
Welcome to The Meb Faber Show, where the focus is on helping you grow and preserve your wealth. Join us as we discuss the craft of investing and uncover new and profitable ideas, all to help you grow wealthier and wiser. Better investing starts here.
Dan Rasmussen & D.A. Wallach on The Future of Biotech and Healthcare | #589
Today’s guests are Dan Rasmussen, founder of Verdad Advisers, and D.A. Wallach, a venture capital investor for Time BioVentures and an acclaimed recording artist. Pharrell Williams discovered D.A.’s band Chester French and signed the group to Interscope Records. In today’s episode, Dan & D.A. discuss the current state of biotech, the impact of AI on healthcare, and the role of innovative treatments in transforming patient care. The three also touch on the shifting narrative of private equity, tax strategies, venture capital returns, and much more.
Key Points
- D. A. Wallach discusses his transition from a career in music to venture capital, emphasizing the need for a cautious approach to investing in the current biotech environment due to increased interest rates and investor shifts towards AI.
- Dan Rasmussen highlights the significant drawdown in biotech valuations, pointing out that traditional value metrics need to be adjusted for biotech companies, and emphasizes the importance of cash runway and spending in evaluating these firms.
- Both guests agree on the challenges and opportunities in private equity, with Dan noting the over-allocation and potential downfalls of private equity investments, while D. A. underscores the need for better tax-efficient investment strategies, particularly in the context of venture capital.
Follow Dan: Website; LinkedIn; X Follow D.A.: Website; LinkedIn; X
Resources: Is private equity becoming a money trap? Zero-Toll Medicine
Chapters
| 0:00 | |
| 1:02 | |
| 7:30 | |
| 19:14 | |
| 33:16 | |
| 41:30 | |
| 59:54 | |
| 1:09:00 | |
| 1:16:39 | |
| 1:19:00 |
Transcript
Loading transcript...
- / -